Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.
about
Psoriatic arthritis: pathogenesis and novel immunomodulatory approaches to treatmentAutoimmune therapies targeting costimulation and emerging trends in multivalent therapeuticsEmerging drugs for moderate-to-severe psoriasis.Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694.High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation.Biologics in dermatologic therapy - an update.New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppressionCladribine and Fludarabine Nucleoside Change the Levels of CD Antigens on B-Lymphoproliferative Disorders.Psoriasis: emerging therapeutic strategies.T cell targeted immunotherapy for autoimmune disease.Emerging drugs for psoriasis.Target Therapy in Hematological Malignances: New Monoclonal Antibodies.Manipulating B cell homeostasis: a key component in the advancement of targeted strategiesTreatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis.Galiximab: a review.Cancer-associated myeloproliferation: old association, new therapeutic target.New antibody drug treatments for lymphoma.Blocking T cell co-stimulation using a CD80 blocking small molecule reduces delayed type hypersensitivity responses in rhesus monkeys.Construction of Macaque Immune-Libraries.Safety and Efficacy of a Milk-Derived Extract in the Treatment of Plaque Psoriasis: An Open-Label Study
P2860
Q24813979-1650BEEE-75E4-4400-B5CC-3A8FF89B2B5FQ26823789-F701F286-3F01-46D0-ABB1-6C26CDDF1C05Q30984470-1B27F3B3-F47C-45C4-8E76-33C5468AD42FQ33220467-DCF11A59-C6AB-4A0D-BD6E-8669BCABF4C6Q33285349-BFB31A6E-59CB-466F-8BC2-234FA85C5089Q33607620-0F6BAE39-C976-4CE3-B3A5-2057CE2F8493Q34175958-3B70A90F-0187-4991-B530-474168DA441CQ35430828-5ABC782B-8797-4D66-820B-2595B339C287Q36028220-29D6AE77-A3F8-4A36-92AA-213EE980F356Q36359571-D503DB72-859D-4062-9C53-7FE13E9CC20AQ36634244-F42FF48F-7B81-4366-BF63-93BC0BBA80D3Q36979140-BB76B77E-749D-488A-885D-4E5A4744E443Q37177128-0E6691BF-BC6F-4115-9413-6566F430EF7BQ37178611-0A6DD59C-5F97-4AE9-AB46-550372390290Q37579811-9CFDBDCE-A629-459E-A856-B9C338555D1EQ37679222-42001DBC-0C3C-44DB-944F-B9D18053F8D4Q37769017-E0DF6672-7D47-4CE2-8DC2-D2D4D162E745Q37852003-A6ECEE64-279C-4E4B-AB7A-88519FB97CECQ39802327-6A7A987B-ACF6-4C8F-8ABF-E5FB52282800Q47369432-B2496819-6FEE-4E86-95F9-06A03A80A5A9Q56906257-F2278688-8A16-4AA1-834F-51686AEFB9FF
P2860
Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Evaluation of safety and clini ...... te to severe plaque psoriasis.
@en
Evaluation of safety and clini ...... te to severe plaque psoriasis.
@nl
type
label
Evaluation of safety and clini ...... te to severe plaque psoriasis.
@en
Evaluation of safety and clini ...... te to severe plaque psoriasis.
@nl
prefLabel
Evaluation of safety and clini ...... te to severe plaque psoriasis.
@en
Evaluation of safety and clini ...... te to severe plaque psoriasis.
@nl
P2093
P1433
P1476
Evaluation of safety and clini ...... te to severe plaque psoriasis.
@en
P2093
Ahsan A Abdulghani
Alan Menter
Alice B Gottlieb
Kenneth G Linden
Mark C Totoritis
Mark Lebwohl
Michael Goldfarb
Nicole Chieffo
Sewon Kang
P356
10.1016/J.CLIM.2004.01.006
P577
2004-04-01T00:00:00Z